GPT and neoplasm: In the ALT positive tumor cohort, the younger age of individuals with IDH1 mutations was significant compared with those without IDH1 mutations (median age 36 versus 52, 25th to the 75th percentile 26–40.5 versus 48–61, p<0.001).